Squarepoint’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.12M Sell
177,571
-29,390
-14% -$273K ﹤0.01% 2684
2025
Q4
$2.54M Buy
206,961
+67,884
+49% +$1.11M ﹤0.01% 1896
2025
Q3
$2.85M Buy
+139,077
New +$2.21M ﹤0.01% 1826
2025
Q2
Sell
-10,746
Closed -$93.1K 4900
2025
Q1
$93.1K Sell
10,746
-30,966
-74% -$189K ﹤0.01% 4237
2024
Q4
$203K Buy
41,712
+31,252
+299% +$175K ﹤0.01% 4465
2024
Q3
$80.8K Sell
10,460
-17,693
-63% -$157K ﹤0.01% 3916
2024
Q2
$282K Buy
+28,153
New +$309K ﹤0.01% 3465
2024
Q1
Sell
-30,971
Closed -$443K 4442
2023
Q4
$443K Buy
30,971
+17,230
+125% +$165K ﹤0.01% 3094
2023
Q3
$107K Sell
13,741
-9,595
-41% -$104K ﹤0.01% 3551
2023
Q2
$333K Buy
+23,336
New +$332K ﹤0.01% 2900
2023
Q1
Sell
-20,116
Closed -$338K 3636
2022
Q4
$338K Sell
20,116
-4,460
-18% -$77.1K ﹤0.01% 2507
2022
Q3
$364K Buy
+24,576
New +$486K ﹤0.01% 2379
2022
Q2
Sell
-30,366
Closed -$1.15M 3234
2022
Q1
$1.15M Buy
30,366
+5,788
+24% +$256K ﹤0.01% 1500
2021
Q4
$1.53M Buy
+24,578
New +$1.86M ﹤0.01% 1419
2021
Q3
Sell
-7,320
Closed -$453K 3280
2021
Q2
$453K Buy
+7,320
New +$373K ﹤0.01% 2218
2020
Q3
Sell
-29,490
Closed -$384K 2743
2020
Q2
$384K Buy
+29,490
New +$321K 0.01% 1451
2019
Q4
Sell
-27,000
Closed -$391K 2715
2019
Q3
$391K Buy
27,000
+5,400
+25% +$83.6K ﹤0.01% 1744
2019
Q2
$350K Buy
+21,600
New +$292K ﹤0.01% 1857

Other funds holding OPRX

Squarepoint's OPRX Position: Q1 2026 in Review

Squarepoint reduced its OptimizeRx (OPRX) stake by 14% in Q1 2026, selling an estimated $273K and leaving 177,571 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2684.

Squarepoint first reported a position in OPRX in Q2 2019 and has held it in 18 quarters since. The position peaked at $2.85M in Q3 2025. 128 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

  • Squarepoint held 177,571 shares of OptimizeRx worth $1.12M as of Q1 2026.
  • Squarepoint sold 29,390 OptimizeRx shares in Q1 2026, an estimated $273K.
  • OptimizeRx made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2684 holding.
  • Squarepoint first reported a position in OptimizeRx in Q2 2019 and has held it in 18 quarters since.
  • Squarepoint's OptimizeRx position peaked at $2.85M in Q3 2025.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.